<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04674345</url>
  </required_header>
  <id_info>
    <org_study_id>Sorafenib-Non-Flt3 AL-2020</org_study_id>
    <nct_id>NCT04674345</nct_id>
  </id_info>
  <brief_title>Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute Leukemia</brief_title>
  <official_title>Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allogeneic Hematopoietic Stem Cell Transplant Recipients With FLT3 Negative Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Chenzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Seventh Affiliated Hospital of Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of sorafenib maintenance&#xD;
      after allo-HSCT in FLT3-negative acute leukemia patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sorafenib is a multikinase inhibitor that blocks multiple pathways involved in the&#xD;
      development and progression of acute leukemia, such as FLT3-ITD, the RAS and RAF gene&#xD;
      families, KIT, and the VEGF and PDGF receptors. Recently, two back-to-back randomized&#xD;
      controlled trials both reveal that sorafenib maintenance after allo-HSCT could prevent&#xD;
      relapse in patients with FLT3-ITD AML, resulting in a survival benefit. Sorafenib has also&#xD;
      been explored in the treatment of acute leukemia without FLT3 mutations and shown promising&#xD;
      results. Currently, relapse remains the major cause of transplant failure, especially for&#xD;
      high-risk and refractory acute leukemia patients. Once patients relapse after allo-HSCT, the&#xD;
      prognosis is dismal. Therefore, prevention of relapse is of great importance to improve the&#xD;
      prognosis. Based on the current research status, we plan to conduct a prospective,&#xD;
      multicenter, phase 2 randomized controlled trial to explore the efficacy and safety of&#xD;
      sorafenib maintenance after allo-HSCT in FLT3-negative acute leukemia patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of leukemia relapse</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia-free survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">346</enrollment>
  <condition>Acute Leukemia</condition>
  <condition>Relapse</condition>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Sorafenib group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib will be administered at 45-60 days post-transplantation and taken for one year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-maintenance group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Neither sorafenib nor other FLT3 inhibitors will be used, unless the patient experiences relapse.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity (dose range, 200-800 mg daily).</description>
    <arm_group_label>Sorafenib group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with FLT3-negative acute leukemia undergoing first allo-HSCT&#xD;
&#xD;
          -  Age 18 to 65 years old with ECOG performance status 0-2&#xD;
&#xD;
          -  Hematopoietic recovery within 60 days post-transplantation&#xD;
&#xD;
          -  Sign informed consent form, have the ability to comply with study and follow-up&#xD;
             procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute promyelocytic leukemia (AML subtype M3)&#xD;
&#xD;
          -  Acute leukemia with FLT3-ITD or FLT3-TKD mutations&#xD;
&#xD;
          -  Philadelphia-positive acute lymphoblastic leukemia&#xD;
&#xD;
          -  Chronic myelogenous leukemia with blast crisis&#xD;
&#xD;
          -  Intolerance to sorafenib pre-transplantation&#xD;
&#xD;
          -  Life expectancy less than 30 days post-transplantation&#xD;
&#xD;
          -  Active aGVHD or uncontrolled infections within 60 days post-transplantation&#xD;
&#xD;
          -  Cardiac dysfunction (particularly congestive heart failure, unstable coronary artery&#xD;
             disease and serious cardiac ventricular arrhythmias requiring antiarrhythmic therapy)&#xD;
&#xD;
          -  Respiratory failure ( PaO2 ≤60mmHg)&#xD;
&#xD;
          -  Hepatic abnormalities (total bilirubin ≥3 mg/dL, aminotransferase &gt;2 times the upper&#xD;
             limit of normal)&#xD;
&#xD;
          -  Renal dysfunction (creatinine clearance rate &lt; 30 mL/min)&#xD;
&#xD;
          -  ECOG performance status 3, 4 or 5&#xD;
&#xD;
          -  With any conditions not suitable for the trial (investigators' decision)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qifa Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Xuan</last_name>
    <phone>+86-020-62787883</phone>
    <email>356135708@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Hematology,Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Xuan</last_name>
      <phone>+86-020-61641613</phone>
      <email>356135708@qq.com</email>
    </contact>
    <investigator>
      <last_name>Qifa Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 14, 2020</study_first_submitted>
  <study_first_submitted_qc>December 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>October 30, 2021</last_update_submitted>
  <last_update_submitted_qc>October 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Qifa Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Acute Leukemia</keyword>
  <keyword>Sorafenib</keyword>
  <keyword>Relapse</keyword>
  <keyword>FLT3-negative</keyword>
  <keyword>Allogeneic hematopoietic stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

